Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).

NCT03632135 is registered in ClinicalTrials.gov with Cordgenics, LLC as lead sponsor.

NCT NCT03632135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03632135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Lead sponsor
Cordgenics, LLC
Phase
Phase 3
Overall status
Completed
Start date
May 20, 2018
Completion date
December 31, 2023
Enrollment
78 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma